ZFIN ID: ZDB-FISH-150901-23010
Fish name: sd2Tg; y1Tg
Genotype: sd2Tg; y1Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by sd2Tg; y1Tg
No data available
GENE EXPRESSION
Gene expression in sd2Tg; y1Tg
RNA expression
Expressed Gene Structure Conditions Figures
cdh5 control Fig. 7 with imageFig. 8 with image from Lalwani et al., 2012
Protein expression
Antibody Antigen Genes Structure Conditions Figures
Ab2-cdh5 cdh5 control Fig. 8 with image from Lalwani et al., 2012
PHENOTYPE
Phenotype in sd2Tg; y1Tg
Phenotype Conditions Figures
blood circulation decreased efficacy, abnormal high cholesterol, high glucose, chemical treatment: metformin Fig. 5 with image from Wang et al., 2013
blood circulation decreased efficacy, abnormal high cholesterol, high glucose, chemical treatment: pioglitazone Fig. 5 with image from Wang et al., 2013
blood circulation decreased efficacy, abnormal high cholesterol, high glucose Fig. 5 with image from Wang et al., 2013
blood circulation decreased functionality, abnormal chemical treatment: drug Fig. 1 with image from Eisa-Beygi et al., 2013
brain hemorrhagic, abnormal chemical treatment: drug Fig. 2 with image from Eisa-Beygi et al., 2013
brain vasculature perforate, abnormal chemical treatment: drug Fig. 3 with image from Eisa-Beygi et al., 2013
head hemorrhagic, abnormal heat shock Fig. 5 from Eisa-Beygi et al., 2018
intersegmental vessel malformed, abnormal chemical treatment: ligand Fig. 6 from Agarwal et al., 2014
nucleate erythrocyte accumulation head, abnormal chemical treatment: drug Fig. 1 with image from Eisa-Beygi et al., 2013
nucleate erythrocyte fragmented, abnormal standard conditions Fig. 3 from Zheng et al., 2019
optic tectum hemorrhagic, abnormal chemical treatment: drug Fig. 2 with image from Eisa-Beygi et al., 2013
pericardium nucleate erythrocyte decreased amount, abnormal chemical treatment: drug Fig. 2 with image from Eisa-Beygi et al., 2013
post-vent region nucleate erythrocyte decreased amount, abnormal chemical treatment: drug Fig. 2 with image from Eisa-Beygi et al., 2013
primitive prosencephalic artery dilated, abnormal chemical treatment: drug Fig. 1 with image from Eisa-Beygi et al., 2013
primordial midbrain channel broken, abnormal heat shock Fig. 5 from Eisa-Beygi et al., 2018
primordial midbrain channel dilated, abnormal chemical treatment: drug Fig. 1 with image from Eisa-Beygi et al., 2013
prosencephalic artery broken, abnormal chemical treatment: drug Fig. 3 with image from Eisa-Beygi et al., 2013
telencephalon hemorrhagic, abnormal chemical treatment: drug Fig. 2 with image from Eisa-Beygi et al., 2013
thoracic duct decreased length, abnormal chemical treatment by environment: vascular endothelial growth factor receptor antagonist Fig. 2 from Li et al., 2016
thoracic duct increased length, abnormal chemical treatment by environment: saponin Fig. 1 from Li et al., 2016
thoracic duct length, ameliorated chemical treatment by environment: vascular endothelial growth factor receptor antagonist, chemical treatment by environment: saponin Fig. 2 from Li et al., 2016
thrombocyte decreased amount, abnormal standard conditions Fig. 3 from Zheng et al., 2019

CITATIONS  (48)